Find Funding Opportunities

Notice Special Interest HEAL Initiative: Request Administrative Supplements Existing Grants Identification Validation New Pain Opioid Disorder Targets within Understudied Druggable Genome Notice Number: NOT-TR-20-008 Key Dates Release Date: March 9, 2020 First Available Due Date: March 17, 2020 Expiration Date: June 02, 2020 Related Announcements PA-18-591 Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) Issued National Center Advancing Translational Sciences NCATS) National Institute Dental Craniofacial Research NIDCR) National Institute Drug Abuse NIDA) National Institute Neurological Disorders Stroke NINDS) National Center Complementary Integrative Health NCCIH) National Institute Arthritis Musculoskeletal Skin Diseases ( NIAMS ) - New participating organization of March 26, 2020 due dates on/after June 01, 2020 Purpose Notice part the NIH Helping End Addiction Long-Term HEAL) Initiative, aggressive, trans-agency effort speed scientific solutions stem national opioid public health crisis. NCATS other participating institutes Centers ICs) inviting investigators relevant active research project grants cooperative agreements submit administrative supplements, according to PA-18-591 Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional), funded projects identify validate new pain opioid disorder OUD) targets within understudied Druggable Genome. Background: human genome revealed great deal the human proteome, though significant portions the genome remain understudied. Only subset expressed proteins demonstrate requisite properties serve targets the development therapeutics. bona fide drug targets likely remain be discovered the Druggable Genome” DG), can defined a subset the 20,000 protein-coding genes the human genome have potential bind drug-like molecules. term drug-like" refers the physical, biochemical, pharmacological attributes small molecule compounds are generally recognized be required efficacious clinical drugs humans. While number proteins the DG upwards 4,500, existing clinical pharmacopeia represented only few hundred targets, leaving huge swath biology remains unexploited. announcement for one-year administrative supplements ongoing funded projects support research will identify validate new targets pain OUD among understudied proteins the Druggable Genome. Kinases such ERK1/2, p38 JNK been shown counteract opioid analgesia precede desensitization the opioid receptors. addition, opioid receptors belong the well-known Gi/o class GPCRs, GPCRs been shown mediate pain neurogenic inflammation. Finally, ion channels been identified critical elements pain signaling transmission. these families contain adequate numbers understudied members are well established druggable families shown be critical pathways associated pain OUD, experimental focus be placed understudied members the families non-olfactory GPCRs, ion channels protein kinases. Eligible understudied proteins listed below considered understudied, they meet following criteria: protein 1) a low number publications/citations, a Jensen Pubmed score Understudied proteins eligible research support under notice: Kinases ADCK1, ADCK2, ADCK5, ALPK2, ALPK3, BCKDK, BRSK1, CAMK1D, CAMK1G, CAMKK1, CAMKV, CDC42BPA, CDC42BPB, CDC42BPG, CDK10, CDK11A, CDK11B, CDK12, CDK13, CDK14, CDK15, CDK16, CDK17, CDK18, CDK19, CDK20, CDKL1, CDKL2, CDKL3, CDKL4, CLK3, CLK4, COQ8A, COQ8B, CSNK1A1L, CSNK1G1, CSNK1G2, CSNK1G3, CSNK2A3, DCLK3, DSTYK, DYRK1B, DYRK2, DYRK3, DYRK4, EEF2K, ERN2, HIPK1, HIPK3, HIPK4, ICK, LMTK2, LMTK3, LRRK1, LTK, MAP3K10, MAP3K14, MAP3K15, MAP3K21, MAPK15, MAPK4, MARK1, MARK3, MARK4, MAST2, MAST3, MAST4, MKNK2, NEK1, NEK10, NEK11, NEK3, NEK4, NEK5, NEK6, NEK7, NEK9, NIM1K, NRBP2, NRK, NUAK2, PAK3, PAK5, PAK6, PAN3, PDIK1L, PHKG1, PHKG2, PI4KA, PIK3C2B, PIK3C2G, PIP4K2C, PIP5K1A, PIP5K1B, PIP5K1C, PKMYT1, PKN3, PNCK, POMK, PRKACB, PRKACG, PRPF4B, PSKH1, PSKH2, PXK, RIOK1, RIOK2, RIOK3, RPS6KC1, RPS6KL1, SBK2, SBK3, SCYL2, SCYL3, SGK494, SRPK3, STK17A, STK17B, STK19, STK3, STK31, STK32A, STK32B, STK32C, STK33, STK36, STK38L, STK40, STKLD1, TAOK1, TAOK2, TBCK, TESK1, TESK2, TLK1, TLK2, TP53RK, TSSK1B, TSSK2, TSSK3, TSSK4, TSSK6, TTBK1, TTBK2, ULK4, VRK2, VRK3, WEE2, WNK2, WNK3 Ion Channels ASIC4, BEST4, CACNA2D2, CACNA2D3, CACNA2D4, CACNG1, CACNG3, CACNG4, CACNG5, CACNG6, CACNG7, CACNG8, CALHM4, CALHM5, CALHM6, CATSPER2, CHRNA10, CHRNB1, CLCA4, CLCC1, CLCN6, CLIC6, GABRP, GPR89A, GPR89B, GRID1, KCNA6, KCNA7, KCNAB2, KCNAB3, KCND1, KCNG2, KCNG3, KCNG4, KCNH4, KCNH6, KCNH8, KCNJ15, KCNJ18, KCNK12, KCNK7, KCNMB3, KCNN1, KCNS1, KCNS2, LRRC38, LRRC55, PKD1L2, PKD1L3, PKD2L2, PLLP, SCN7A, SLC26A1, TMC3, TMC4, TMC5, TMC7, TMEM38B, TMEM63A, TMEM63B, TTYH1, TTYH2 G-Protein Coupled Receptors GPCRs) ADGRA1, ADGRA3, ADGRB2, ADGRB3, ADGRD1, ADGRD2, ADGRE1, ADGRE3, ADGRF1, ADGRF2, ADGRF3, ADGRF4, ADGRF5, ADGRG2, ADGRG3, ADGRG4, ADGRG5, ADGRG7, FZD10, GNRHR2, GPR101, GPR12, GPR135, GPR137, GPR139, GPR141, GPR142, GPR146, GPR149, GPR150, GPR151, GPR152, GPR153, GPR156, GPR157, GPR160, GPR162, GPR171, GPR173, GPR174, GPR18, GPR19, GPR20, GPR21, GPR22, GPR25, GPR26, GPR27, GPR3, GPR31, GPR32, GPR34, GPR37L1, GPR4, GPR45, GPR52, GPR6, GPR61, GPR62, GPR63, GPR65, GPR68, GPR75, GPR78, GPR82, GPR85, GPR87, GPR88, GPRC5A, GPRC5B, GPRC5C, GPRC5D, HCAR1, HCAR3, LPAR6, MRGPRE, MRGPRF, MRGPRG, MRGPRX1, MRGPRX2, MRGPRX3, MRGPRX4, NPBWR1, NPBWR2, OXER1, OXGR1, P2RY10, PROKR1, QRFPR, RXFP4, TAAR2, TAAR3P, TAAR8, TAAR9, TAS2R1, TAS2R10, TAS2R13, TAS2R14, TAS2R16, TAS2R19, TAS2R20, TAS2R3, TAS2R30, TAS2R31, TAS2R39, TAS2R4, TAS2R40, TAS2R41, TAS2R42, TAS2R43, TAS2R46, TAS2R5, TAS2R50, TAS2R60, TAS2R7, TAS2R8, TAS2R9 Examples potential research areas include would be limited to: Isolation purification understudied proteins and in vitro/in vivo characterization the intent developing novel therapeutics; Validation placement understudied protein(s) signaling cascades, including upstream signals downstream activities order better understand pain OUD targets; Pre-clinical animal studies understudied Druggable Genome candidate proteins focused therapeutic development development candidate therapeutics; Characterization cell- tissue-specific protein expression, localization, function understudied protein(s) native environments they pertain pain OUD; of novel tools validate preliminary disease physiological associations understudied proteins animal models, biomimetic systems, or ex vivo human samples; Studies establish preliminary structure-activity-relationships SAR) between functions an understudied protein its ligands e.g., small molecules, macrocycles, synthetic peptides) future drug discovery projects. work proposed must within scope the existing award. Before submitting supplement request, principal investigators strongly encouraged contact appropriate IC contact listed the end this notice any questions to discuss whether proposed supplement within scope the parent award consistent the priorities the IC supporting parent award. Applications must include detailed description the proposed activities a justification the proposed work within scope the existing award. Sufficient justification should provided indicate why particular protein(s) chosen study. Those projects employing methods identify multiple proteins study the above lists acceptable require justification to why those proteins chosen, beyond fact they on eligible protein lists provided. Applications must also demonstrate adequate progress date the parent study. activities proposed the supplement must able be accomplished within current competitive segment. Award Project Period be eligible, parent award must active FY20 i.e., parent award received funds FY20 is in extension period), the research proposed the supplement should requested 1 year. earliest anticipated start date June 1, 2020. Budget Supplement budget requests cannot exceed 99,999 direct costs excluding subcontract F&A). Requests must reflect actual needs the proposed project. Requests be one year support only. Modular categorical budgets permitted. Eligible Individuals Program Director/Principal Investigator) Individual(s) must hold active grant cooperative agreement. supplements parent awards include multiple PDs/PIs, supplement be requested any all the PDs/PIs accordance the existing leadership plan) submitted the awardee institution the parent award Application Submission Information Applications this initiative must submitted using following opportunity its subsequent reissued equivalent. PA-18-591 - Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) instructions the SF424 R&R) Application Guide and PA-18-591 must followed, the following additions: Requests must received 5:00 PM local time applicant organization June 1, 2020 funding FY 2020. Application Due Date(s) – June 1, 2020, 5:00 PM local time applicant organization. funding consideration, applicants must include NOT-TR-20-008” without quotation marks) the Agency Routing Identifier field box 4B) the SF424 R&R form. Applications without information box 4B not considered this initiative. Requests be one year support only. be eligible, parent award must active FY20 i.e. applications a no-cost extension not eligible apply.). earliest anticipated start date June 1, 2020. Research Strategy section the application limited 6 pages. process Streamlined Submissions using eRA Commons cannot used this initiative. Applicants strongly encouraged notify program contact the Institute supporting parent award a request been submitted response this FOA order facilitate efficient processing the request. Supplement budget requests cannot exceed 99,999 direct costs excluding subcontract F&A) one year. Requests must reflect actual needs the proposed project. Modular categorical budgets permitted Individual(s) must hold active grant cooperative agreement. supplements parent awards include multiple PDs/PIs, supplement be requested any all the PDs/PIs accordance the existing leadership plan) submitted the awardee institution the parent award. Inquiries Please direct inquiries to: Karlie Sharma, Ph.D. National Center Advancing Translational Sciences NCATS) Telephone: 301-451-4965 Email: Karlie.Sharma@nih.gov  

Notice Special Interest Encourage Eligible NIH HEAL Initiative Awardees Apply PA-18-906 Research Supplements Promote Diversity Health-Related Research Admin Supp - Clinical Trial Allowed) Notice Number: NOT-NS-20-023 Key Dates Release Date: March 3, 2020 First Available Due Date: April 15, 2020 Expiration Date: June 30, 2020 Related Announcements PA-18-906 - Research Supplements Promote Diversity Health-Related Research Admin Supp - Clinical Trial Allowed) Issued National Institute Neurological Disorders Stroke NINDS) National Institute Alcohol Abuse Alcoholism NIAAA) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Biomedical Imaging Bioengineering NIBIB) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Dental Craniofacial Research NIDCR) National Institute Diabetes Digestive Kidney Diseases NIDDK) National Institute Drug Abuse NIDA) National Institute Mental Health NIMH) National Center Complementary Integrative Health NCCIH) National Center Advancing Translational Sciences NCATS) National Cancer Institute NCI) applications this funding opportunity announcement should fall within mission the Institutes/Centers. following NIH Offices co-fund applications assigned those Institutes/Centers. Office Behavioral Social Sciences Research OBSSR) Purpose NIH a strong interest the diversity the NIH-funded research enterprise the recently funded NIH notice NOT-OD-20-031) encourages institutions diversify scientific workforce enhancing participation individuals groups identified underrepresented the biomedical, clinical, behavioral, social sciences. Participating institutes continue support efforts through ongoing programs supplement funding opportunities. specific notice reiterates interest encourages eligible grant cooperative agreement awardees the HEAL Initiative community apply administrative supplements response to PA-18-906, Research Supplements Promote Diversity Health-Related Research Admin Supp - Clinical Trial Allowed). notice part the NIH’s Helping End Addiction Long-term HEAL) Initiative speed scientific solutions the national opioid public health crisis. NIH HEAL Initiative bolster research across NIH 1) improve treatment opioid misuse addiction 2) enhance pain management. information the HEAL Initiative available at: https://heal.nih.gov/ Application Submission Information Applications this initiative must submitted using following opportunity its subsequent reissued equivalent. PA-18-906 - Research Supplements Promote Diversity Health-Related Research Admin Supp - Clinical Trial Allowed) instructions the SF424 R&R) Application Guide and PA-18-906 must followed, the following additions: Application Due Date(s) – April 15, 2020 June 1, 2020 5:00 PM local time applicant organization. funding consideration, applicants must include ldquo;NOT-NS-20-023” without quotation marks) the Agency Routing Identifier field box 4B) the SF424 R&R form. Applications without information box 4B not considered this initiative. Research Strategy section the application limited 6 pages. Only existing awardees the HEAL Initiative program eligible apply. process Streamlined Submissions using eRA Commons cannot used this initiative. Applicants strongly encouraged notify program contact the Institute supporting parent award well as Alex.Tuttle@nih.gov that request been submitted response this FOA order facilitate efficient processing the request. the first sentence the Research Strategy, applicants requested state the parent grant awarded a HEAL Initiative award to identify specific FOA the parent grant e.g., RFA-NS-19-016) facilitate processing the supplement application. HEAL diversity supplement awardees strongly encouraged participate annual PD/PI meetings in activities their mentors. Applicants request funds, addition the research costs specified in PA-18-906, enable supplement candidate attend annual HEAL Initiative PD/PI meeting the Washington, DC area. request additional funds should reasonable well justified the application. Potential applicants strongly encouraged review the supplemental guidance for diversity supplement applications the NINDS web site. Consultation the Program Official the qualifying HEAL award the individual named under Inquiries below highly recommended. Supplement applications be evaluated the HEAL Initiative diversity committee. Applications non-responsive terms this NOSI be be considered the NOSI initiative. Inquiries Please direct inquiries to: Eric Hudak, PhD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-1779 Email: Eric.Hudak@nih.gov

Notice Special Interest NOSI): Administrative Supplements Support Enhancement Software Tools Open Science Notice Number: NOT-OD-20-073 Key Dates Release Date: March 3, 2020 First Available Due Date: 15, 2020 Expiration Date: 16, 2020 Related Announcements PA-18-591Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Administrative SupplementClinical Trial Optional) Issued Office The Director, National Institutes Health OD) National Eye Institute NEI) National Heart, Lung, Blood Institute NHLBI) National Human Genome Research Institute NHGRI) National Institute Aging NIA) National Institute Alcohol Abuse Alcoholism NIAAA) National Institute Allergy Infectious Diseases NIAID) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Biomedical Imaging Bioengineering NIBIB) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Deafness Other Communication Disorders NIDCD) National Institute Dental Craniofacial Research NIDCR) National Institute Diabetes Digestive Kidney Diseases NIDDK) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) National Institute General Medical Sciences NIGMS) National Institute Mental Health NIMH) National Institute Neurological Disorders Stroke NINDS) National Institute Nursing Research NINR) National Institute Minority Health Health Disparities NIMHD) National Library Medicine NLM) Fogarty International Center FIC) National Center Complementary Integrative Health NCCIH) National Center Advancing Translational Sciences NCATS) National Cancer Institute NCI) Purpose Notice announces availability administrative supplements active grants focus biomedical software development have significant software development component. goal these supplements to invest research software tools recognized value a scientific community enhance impact leveraging best practices software development advances cloud computing. initiative part a plan implementing theNIH Strategic Plan Data Science, describes actions aimed modernizing biomedical research data ecosystem making data FAIR findable, accessible, interoperable, reusable) high impact open science. supplements intended support collaborations between biomedical scientists software engineers enhance design, implementation, cloud-readiness research software. Through awards, NIH Office Data Science Strategy ODSS) intends help researchers have developed scientifically valuable software make tools sustainable, contribute open science, take advantage new data science computing paradigms. Background part their research projects, investigators often produce innovative, scientifically valuable software tools. tools enabled scientists efficiently process manage data, mine, analyze, visualize, interpret results. However, much this valuable software been built supported under conditions are longer optimal a rapidly changing landscape. Additionally, investigators lack resources adapt revise software take advantage new computing paradigms to robust, sustainable, accessible a broader community. opportunity intended help researchers redeploy research software tools be robust sustainable a shared data ecosystem envisioned the NIH ODSS. challenges considerable. example, tools developed customized data held on-premises, often optimized local computing platforms including supporting libraries) cannot readily scaled applied open science data, such those stored a cloud environment. Software tools most often developed academic settings absence input research software engineers can aid this transition operational efficiency sustainability. have few practical ways support joint efforts between researchers software engineers skills develop revise research tools robust design, accessibility scalability modern computing platforms. traditional grant funding process emphasized innovation research progress over use software engineering best-practices design principles, are essential reliability sustainability an era large-scale, integrated data. is NIH vision establish modernized integrated biomedical data ecosystem adopts latest data science technologies, including cloud computing, best practice guidelines arising community consensus, such the FAIR principles open-source development. effort described the NIH Data Science Strategic Plan led the newly established ODSS. addition major efforts IT infrastructure, data resources, workforce development, policy considerations, data science strategic plan includes goals enhance software workflows the modern data ecosystem. Research Objective goal this Notice Special Interest NOSI) to encourage researchers engage new types collaborations focus research software. Supplements support efforts address robustness, sustainability, reusability, scalability existing biomedical research software tools workflows recognized scientific value. efforts expected adhere software engineering best practices design principles take significant steps toward sustainability open source cloud-based environments. broad range projects have significant biomedical research software workflow development components eligible, regardless the scientific area emphasis. scope each proposed project defined and limited the aims the funded project which supplement being sought. Significant software engineering skills expected be needed develop robust implementations to adapt software changing computing paradigms. Thus, supplements primarily intended provide support software engineering staff storage computing costs are required test software revisions. Delivering reliable, sustainable, reusable software across multiple platforms a whole-lifecycle effort, illustrated the following examples. Software development be improved enhancements the development environment, including resources building, testing, community contribution. Engaging community improve robustness making code available appropriate open source licensing. Compliance open interfaces data formats be added enhance interoperability reusability. Refactoring be performed take advantage new hardware compute environments e.g., parallelizing process using standard workflow language can run cloud environments). Reusability be enhanced improving dissemination channels important algorithms tools e.g., inclusion package distribution channels), publication tools shared container registries, by refinement operating manuals. Projects propose test cloud-readiness a local, commercial, public cloud environment. Working the NIH STRIDES initiative https://datascience.nih.gov/strides) strongly encouraged. Cloud readiness a blanket term can encompass range activities. this announcement cloud readiness refers adapting cloud architecture extending usefulness software. Examples produce robust, sustainable cloud-ready research software include, are limited to: Adding APIs services reducing coupling complex shared state Decomposing decoupling services explicitly encoded data sources Employing standard security relies cloud Identity Access Management IAM) models Improving architecture reduce chattiness over network to minimize data ingress/egress charges cloud environments Adopting standard input output data formats Factoring configuration services environment variables configuration properties deployment Implementing standard logging models Converting tools provide clean input, output, configuration make more usable composition via workflow languages such CWL WDL Enhancing source code build/test tools support community open source development, developing standard build packaging tools manage dependencies produce containerized runtimes formatting packages sharing via common package management tools appropriate the language environment Enhancing standard unit functional testing support sample data sets testing patches upgrades supplement application must demonstrate use best software engineering practices design principles. Examples relevant projects address or of challenges toward becoming ready open science cloud environment include, are limited to: Provisioning standard source code structure, documentation, version management, build test support codebases promotes community open source enhancement. Refactoring software incorporate standard interfaces data formats, replacement built-in dependencies standard hardened libraries. Adding APIs services software, especially compliant community standards Refactoring software scale efficiently the cloud. Containerization software entry a tool registry. Enhancing usability, interoperability scalability under increasing load, including making of enhanced hardware clustering technology. Enhancing data security privacy protection. Projects involving significant new scientific features opposed software engineering NOT appropriate this NOSI. Possible exceptions include enhanced data security privacy functions. Projects no active software development components would to add are eligible this NOSI. Application Submission Information Budget be eligible, parent award must able receive funds FY2020 Oct. 1, 2019 - Sept. 30, 2020) not in final year in no-cost extension period the time the award. One-time supplement budget requests cannot exceed 150,000 direct costs. number awards be contingent availability funds receipt meritorious applications. is currently anticipated 6-10 awards be made. Eligible Activity Codes: Administrative supplement requests be submitted the following activity codes:R01, U01,R03,R00, R21, R33, R35, R37, R61 Centers multi-project grant mechanisms not eligible. Additional Information Applications this initiative must submitted usingPA-18-591- Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) its subsequent reissued equivalent. instructions theSF424 R&R) Application Guideand PA-18-591 must followed, the following additions: Application Due Date(s) May 15, 2020 5:00 PM local time applicant organization. funding consideration, applicantsmust include NOT-OD-20-073" without quotation marks) the Agency Routing Identifier field box 4B) the SF424 R&R form. Applications without information box 4Bwill be consideredfor initiative. Requests be one year support only. Research Strategy section the application islimited 3 pages. Research Strategy should include justification significant user base cloud readiness, timelines activities proposed, indication how supplement uses best software engineering practices design principles. Electronic submissions arerequiredfor funding opportunity. process Streamlined Submissions using eRA Commons cannot used this initiative. Administrative Evaluation Process Submitted applications must follow guidelines the IC funds parent grant. Administrative Supplements not receive peer review. IC conduct administrative reviews applications submitted their IC separately. most meritorious applications be evaluated a trans-NIH panel NIH staff supported based upon availability funds. criteria described below be considered the administrative evaluation process: the work proposed within scope the active award? the active award be supplemented focused software tool/workflow development, is a significant component the award? Does user base justify additional support? the proposed project technically feasible within supplement's funding period? the proposed timelines adequate realistic? the proposed supplement project focused software engineering robust, sustainable software is cloud ready opposed enhancing scientific value)? Does project demonstrate sound software development practices, improve performance, interoperability, portability reliability, community engagement, sustainability, adoption? Information: is strongly recommended the applicants contact respective program officers the Institute supporting parent award advance to: Confirm the supplement falls within scope the parent award; Request requirements the IC submitting applications administrative supplements Investigators planning submit application response this NOSI also strongly encouraged contact discuss proposed research/aims the scientific contact listed this NOSI advance the application receipt date. Following submission, applicants strongly encouraged notify program contact the IC supporting parent award a request been submitted response this FOA order facilitate efficient processing the request. Inquiries Please direct inquiries to: Jessica Mazerik, Ph.D.Office Data Science StrategyDivision Program Coordination, Planning, Strategic InitiativesOffice the DirectorJessica.mazerik@nih.gov

Reissue of PAR-18-541. The Blueprint Neurotherapeutics Network (BPN) encourages applications from small businesses seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry to the Development stage, to advance a single development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Alternatively, projects can enter at the Development stage and progress in a shorter period to IND enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.

Reissue of PAR-18-546. The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry to the Development stage, to advance a single development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Alternatively, projects can enter at the Development stage and progress in a shorter period to IND enabling toxicology studies and phase I clinical testing. BPN awardee Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.

Notice Special Interest NOSI): Availability Administrative Supplements the Rare Disease Clinical Research Network RDCRN) Notice Number: NOT-TR-20-006 Key Dates Release Date: February 27, 2020 First Available Due Date: April 01, 2020 Expiration Date: April 04, 2022 Related Announcements RFA-TR-18-020 Rare Diseases Clinical Research Consortia RDCRC) the Rare Diseases Clinical Research Network RDCRN) U54 Clinical Trial Optional) PA-18-591 Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) Issued National Center Advancing Translational Sciences ( NCATS) National Heart, Lung, Blood Institute NHLBI) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Diabetes Digestive Kidney Diseases NIDDK) National Institute Neurological Disorders Stroke NINDS) Purpose National Center Advancing Translational Sciences NCATS) informs Program Directors/Principal Investigators PDs/PIs) holding active Rare Diseases Clinical Research Consortia RDCRC) the Rare Diseases Clinical Research Network RDCRN) U54) awards the opportunity submit administrative supplement requests through NIH Parent Funding Opportunity Announcement FOA), PA-18-591, ldquo;Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional)”. supplements provide short-term and/or catalytic support projects a significant unmet needs. Applicants the administrative supplements encouraged form new collaborations enhance reach impact the activity. Administrative supplements must add value the science proposed the aims the original project; such, they must within scientific scope the parent grant. Enthusiasm be higher requests describe clear outcome that the potential greatest impact across RDCRN these outcomes be subsequently distributed shared throughout consortium. RDCRN Program also identified specific areas interest accordance its aim to advance diagnosis, management, treatment rare diseases a focus clinical trial readiness. The RDCRN priority research areas would appropriate requests supplemental funding include, are limited to, topics listed here: Methods accelerate diagnosis Genomic analysis/characterization, interpretation e.g., Gene Curation leveraging ClinGen resources) Novel precision personalized approaches treatment Outreach increase research participant diversity Addressing health disparities Expanding focus women’s health Expanding focus mental health issues Expanding age range research participants Evolving technologies e.g., remote data capture, augmented reality) facilitate assessment, management treatment rare diseases. Trans-network research common interests e.g., shared molecular etiologies, research data collections approaches) Administrative supplement requests support clinical trials not accepted and/or considered response this funding opportunity announcement. Applications should demonstrate the supplement be completed within project period. applicable, proposed research effort should supported a strong rationale should contribute advancing translational sciences. Applicants strongly encouraged discuss potential requests their Program Official listed the Notice Grant Award the parent grant. Award Project Period Administrative supplements limited 12 months. Budget Available Funds Supplement budget requests not exceed 150,000 per year direct costs must reflect actual needs the proposed project. is guarantee funds available NCATS for any specific grant. Application Submission Information Eligible Individuals Program Director/Principal Investigator) Applicants must hold active RDCRN award: only parent RDCRN cooperative agreement awards funded through following FOA any reissues this announcement) eligible request supplemental funding under NOSI: RFA-TR-18-020: Rare Diseases Clinical Research Consortia RDCRC) the Rare Diseases Clinical Research Network RDCRN) U54 Clinical Trial Optional) supplements parent awards include multiple PDs/PIs, supplement be requested any all the PDs/PIs accordance the existing leadership plan) must submitted the awardee institution the parent award. Submitting Application Applications this initiative must submitted using following opportunity its subsequent reissued equivalent. PA-18-591 - Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) instructions the SF424 R&R) Application Guide and PA-18-591 must followed, the following additions: funding consideration, applicants must include ldquo;NOT-TR-20-006” without quotation marks) the Agency Routing Identifier field box 4b) the SF424 R&R form. Applications without information box 4b not considered this initiative. facilitate efficient processing the request, applicants strongly encouraged notify Tiina Urv urvtiin@mail.nih.gov), well the assigned IC program officer IC grants management specialist the parent award a request been submitted response this NOSI. Research Strategy section the application limited to 6 pages. Applicant organizations submit only application per fiscal year this NOSI. process Streamlined Submissions using eRA Commons cannot used this initiative. applications must submitted electronically using single-project application form package. Please note, for single multi-project applications applicants must the form package the Competition ID ldquo;FORMS-E-ADMINSUPP-RESEARCH". one the methods described PA-18-591. Paper submissions applications submitted attachments be returned. Application Due Date – April 1, 2020; April 1, 2021; April 1, 2022, 5:00 PM local time applicant organization. Inquiries Please direct inquiries to: Tiina K. Urv, Ph.D. National Center Advancing Translational Sciences NCATS) Telephone: 301-827-2746 Email: urvtiin@mail.nih.gov

This Funding Opportunity Announcement (FOA) solicits applications to develop standards that describe experimental protocols that are being conducted as part of the BRAIN Initiative. It is expected that applications will solicit community input at all stages of the process. It is recommended that the first step of standard development will involve sharing data between different key groups in the experimental community in order to ensure that the developing standard will cover the way that all of those groups are collecting data. The developed standard is expected to be made widely available.

This funding opportunity announcement (FOA) invites applications to develop a multisite, longitudinal, prospective study of idiopathic REM sleep behavior disorder (iRBD) as a prodromal phase of ?-synuclein neurodegenerative disorders.

This Funding Opportunity Announcement (FOA) is aimed at discovering, characterizing the selectivity and sensitivity, and externally validating biological measures to be used for assessing, prognosing, and monitoring recovery of adolescents who either clinically present with or are at risk for developing prolonged/persistent concussive symptoms following exposure to repetitive head impacts and/or concussion. Resultant biological measures should be incorporated into risk stratification algorithms to inform clinical care and patient stratification for future clinical trials. A critical feature of this FOA includes the broad sharing of clinical, neuroimaging, physiological, and biospecimen data to further advance research in the area of persistent concussive symptoms in early and middle adolescent (EMA; ages 11-17 years old) populations.

The purpose of this PAR is to support the development and evaluation of non-viral technologies to deliver genome editors to disease relevant somatic cells and tissues in vivo. The ultimate goal of these technologies is translation into clinical trials of genome editing to treat human disease.